Our Programs
Biomanufacturing@MIT-CBI advances technology, training, and knowledge networks in biomanufacturing with the overarching goal of advancing the safe, timely, and efficient production and delivery of biologic medicines. We pursue these goals through a range of activities, including our pre-competitive, collaborative consortia, our development of educational programs, and our sponsored research projects.
Biomanufacturing@MIT-CBI
Consortia & Programs
BioACCESS is an initiative aimed at enabling global access to biologic therapies, especially for non-communicable diseases in resource-constrained settings, through innovative approaches to systems analysis, technology development, policy design, and education.
BioMAN seeks to develop new knowledge, science, technologies and strategies that advance the manufacture and global delivery of high-quality biopharmaceuticals.
The mission of the CAACB is to pool biopharmaceutical manufacturing expertise in the area of adventitious agent contamination to better enable the safe and reliable delivery of biologics.
MIT’s NEW Drug Development ParadIGmS (NEWDIGS) program is a unique collaborative “think and do” tank focused on enhancing the capacity of the global biomedical innovation system to reliably and sustainably deliver new, better, affordable therapeutics to the right patients faster. MIT NEWDIGS takes a systems approach to designing, evaluating and catalyzing important advancements that are so complex and cross-cutting that they cannot be addressed by a single organization or market sector. Its first project area was focused on catalyzing the evolution of global pharmaceutical regulation.
NEWDIGS
Projects
Medical research is making significant advances toward treatments that cure major diseases, but these treatments will often entail very high up-front costs. The FoCUS Project seeks to collaboratively address the need for new, innovative financing and reimbursement models for durable therapies in the US.
The goal of the LEAPS Project is to design and pilot an innovation ecosystem for one disease that drives more value, faster, to patients, in ways that work for all stakeholders.